StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Naratriptan

HCID 4440
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
121679-13-8
Standard-SMILES
CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1
InChIKey
AMKVXSZCKVJAGH-UHFFFAOYSA-N
Summenformel
C17H25N3O2S
Durchschnittliche Molmasse
335,5 g/mol
Monoisotopische Masse
335,16674804

Überblick

Naratriptan is a member of tryptamines, a sulfonamide and a heteroarylpiperidine. It has a role as a serotonergic agonist and a vasoconstrictor agent.

Namen und Bezeichner

Bevorzugter Name
Naratriptan
IUPAC
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
Englischer Name
Naratriptan
Summenformel
C17H25N3O2S
Molmasse
335.46

Namen und Synonyme

naratriptan121679-13-8NaramigN-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamidenaratriptanum1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamideQX3KXL1ZA2N-Methyl-2-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)ethanesulfonamideN-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamideCHEBI:7478DTXSID7023354
Weitere Namen anzeigen
Naratriptan1NaratriptaneNaratriptan(Amerge)Naratriptan, 10 mM in DMSOAMERGEGR-85548AN-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]ethanesulfonamideInhibitor,GR-85548A,5-hydroxytryptamine Receptor,inhibit,Serotonin Receptor,5-HT Receptor,Naratriptan
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethane-1-sulfonamideN-methyl-2-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)ethane-1-sulfonamideN-methyl-2-(3-(1-methyl-4-piperidyl)-1H-indol-5-yl)-ethanesulfonamideRefChem:57988DTXCID003354N02CC02N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide601-800-8

Eigenschaften

Berechnete Struktureigenschaften

XLogP
2
Polarare Oberfläche (TPSA)
73,6 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
5
Schwere Atome
23
Formalladung
0
Komplexität
483

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP1.6
Solubility1.14e-01 g/L
Human Drugs · 2 Einträge

Breast Feeding; Lactation; Milk, Human; Serotonin Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Triptans; Vasoconstrictor Agents

Pharmaceuticals

Melting Point246 °C (hydrochloride salt)
Physical DescriptionSolid
Collision Cross Section174.3 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physikochemische Eigenschaften

Schmelzpunkt
170 · 170-171°
Siedepunkt

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Treatment · 1 Eintrag

There is no specific antidote to naratriptan. Standard supportive treatment should be applied as required. If the patient presents with chest pain or other symptoms consistent with angina pectoris, ECG monitoring should be performed for evidence of ischemia. (L1712)

Exposure RoutesWell absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack.
Toxicity Summary · 1 Eintrag

Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.

Signs and SymptomsSymptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

naratriptan

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

N02CC02

N - Nervous system

QN - Nervous system

Protein Binding28%-31% (over the concentration range of 50 to 1000 ng/mL)
Pharmacodynamics · 1 Eintrag

Naratriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonist. Naratriptan has only a weak affinity for 5-HT<sub>1A</sub>, 5-HT<sub>5A</sub>, and 5-HT<sub>7</sub> receptors and no significant affinity or pharmacological activity at 5-HT<sub>2</sub>, 5-HT<sub>3</sub> or 5-HT<sub>4</sub> receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Naratriptan also activates 5-HT<sub>1</sub> receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Naratriptan in humans.

Mechanism of Action · 1 Eintrag

Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.

Biological Half-Life5-8 hours
Metabolism/Metabolites · 2 Einträge

Primarily hepatic. <i>In vitro,</i> naratriptan is metabolized by a wide range of cytochrome P450 isoenzymes into a number of inactive metabolites.

Primarily hepatic. <i>In vitro,</i> naratriptan is metabolized by a wide range of cytochrome P450 isoenzymes into a number of inactive metabolites. Half Life: 5-8 hours

Zugehörige Reaktionen

8
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 94643
HRID 94643als Produkt
Reaktionsgleichung von HRID 358594
HRID 358594als Produkt
Reaktionsgleichung von HRID 358595
HRID 358595als Edukt
Reaktionsgleichung von HRID 358597
HRID 358597als Edukt
Reaktionsgleichung von HRID 1028409
HRID 1028409als Edukt
Reaktionsgleichung von HRID 1028410
HRID 1028410als Produkt
Reaktionsgleichung von HRID 1028422
HRID 1028422als Edukt
Reaktionsgleichung von HRID 1028423
HRID 1028423als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
121679-13-8
PubChem CID
4440
DTXSID
DTXSID7023354
ChEMBL
CHEMBL1278
ChEBI
CHEBI:7478
UNII
QX3KXL1ZA2
EC Number
601-800-8
Nikkaji
J550.688C
541.3 · 541.3±60.0 °C(Predicted)
Dichte
1.227 · 1.227±0.06 g/cm3(Predicted)
pka
11.52 · 11.52±0.40(Predicted)
FDA Pharmacological Classification · 6 Einträge

QX3KXL1ZA2

NARATRIPTAN

Mechanisms of Action [MoA] - Serotonin 1b Receptor Agonists

Mechanisms of Action [MoA] - Serotonin 1d Receptor Agonists

Established Pharmacologic Class [EPC] - Serotonin-1b and Serotonin-1d Receptor Agonist

Naratriptan is a Serotonin-1b and Serotonin-1d Receptor Agonist. The mechanism of action of naratriptan is as a Serotonin 1b Receptor Agonist and Serotonin 1d Receptor Agonist.

MeSH Pharmacological Classification · 2 Einträge

Drugs used to cause constriction of the blood vessels.

Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes.

Absorption, Distribution and Excretion · 3 Einträge

Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack.

170 L

6.6 mL/min/kg

Cellular LocationsCytoplasm

Verwendung und Herstellung

Uses · 2 Einträge

Use (kg; approx.) in Germany (2009): >10

For the acute treatment of migraine attacks with or without aura in adults.

Use ClassificationPharmaceuticals

Anwendungen

VerwendenNaratriptan is a triptan drug that is used for the treatment of migraine headaches.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

1-Methyl-4-piperidon(1-Methyl-piperidin-4-yl)-acetaldehydePalladiumdihydroxidOxalsäureN-Methyl-1H-Indole-5-EthaneSulphonamide